Skip to main content
. 2020 May 14;2020:4593412. doi: 10.1155/2020/4593412

Table 3.

Summary of adverse reactions.

Study ID Experimental group Control group
Sample size Intervention Specific case Sample size Intervention Specific case
Liu [39] 36 SP (ZFCT[po, 40 mg, tid]) + CPT Rash or pruritus: 2; gastrointestinal upset: 3; decreased WBC: 1 32 SSZ Rash or pruritus: 1; gastrointestinal upset: 3; headache: 1
Liu [40] 30 SP (ZFCT[po, 80 mg, tid]) + CPT 0 20 SSZ 0
Dong [41] 45 SP (ZFCT[po, 40 mg, tid]) + CPT Gastrointestinal upset: 2; drug allergy (SP): 2 34 SSZ + Meloxicam Gastrointestinal upset: 2; drug allergy (SSZ): 1
Yang [42] 38 SP (ZFSRT[po, 60 mg, bid]) + CPT Rash or pruritus: 4 38 SSZ 0
Huang [43] 13 SP (ZFSRT[po, 60 mg, bid]) + CPT Rash or pruritus: 1 12 SSZ Liver and kidney dysfunction: 2
Yin [44] 31 SP (ZFSRT[po, 60 mg, bid]) + CPT Rash or pruritus: 5; gastrointestinal upset: 3; decreased WBC: 2; liver and kidney dysfunction: 1; RBC urine: 4 30 SSZ Rash or pruritus: 1; gastrointestinal upset: 2; decreased WBC: 2; liver and kidney dysfunction: 2; RBC urine: 3
Lin [45] 57 SP (ZFSRT[po, 120 mg, bid]) + CPT Rash or pruritus: 5; gastrointestinal upset: 7; elevated transaminase: 5 58 SSZ + NSAIDs + methotrexate Rash or pruritus: 6; elevated transaminase: 6
Jie [47] 32 SP (ZFI[intra-articular injection, 35 ml, once a week]) + CPT Rash or pruritus: 5; dizziness: 1 30 SSZ/Meloxicam 0
Liu [49] 60 SP (ZFSRT[po, 60 mg, bid]) Rash or pruritus: 3 60 SSZ Rash or pruritus: 7; elevated transaminase: 3
Chai [50] 28 SP (ZFSRT[po, 120 mg, bid]) Rash or pruritus: 1; gastrointestinal upset: 3; headache: 1 22 SSZ Rash or pruritus: 2; gastrointestinal upset: 3; decreased WBC: 1

Note. ZFCT: Zhengqing Fengtongning Conventional Tablet; ZFSRT: Zhengqing Fengtongning Sustained Release Tablet; ZFI: Zhengqing Fengtongning Injection; SSZ: sulfasalazine; NSAIDs: nonsteroidal anti-inflammatory drugs; IPT: inflammatory pain tablet; po: oral preparation; tid: three times a day; bid: twice a day; WBC: white blood cell; RBC: red blood cell.